• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Alerts
CMECNE

NCCN: New Genetic Risk Assessment Recommendations for Breast, Ovarian and Pancreatic Cancers

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Describe the changes in the December 2019 NCCN guidelines for breast, ovarian and pancreatic genetic cancer testing
2. State the concerns regarding the use of direct-to-consumer genetic cancer testing

Estimated time to complete activity: 0.25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG
President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from 1/15/2020 through 1/15/2021, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon registering and successfully completing the post-test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.2 contact hours.

Read Disclaimer & Fine Print

SUMMARY:

NCCN has updated their guidelines (December 2019) on screening for those who may be at high risk for breast, ovarian or pancreatic cancers. There are some important changes addressed in these new recommendations, including the following

  • Pancreatic cancer has been included in the title of the document with a separate section
  • The document, as in previous iterations, focuses on BRCA1/2
    • However, in addition, other high and moderate penetrance genes are now included
  • Individuals of Ashkenazi Jewish (AJ) heritage can be considered for genetic testing even if unaffected and in the absence of family history

KEY POINTS:

Pancreatic Cancer

  • 4-10% of individuals with pancreatic cancer can be carriers of pathogenic variants in genes that confer high or moderate risk
  • A pathogenic mutation may be present even in the absence of the typical clues such as early age at diagnosis or strong family history
  • As a result of the above, NCCN recommends that genetic counseling and testing be offered to
    • All individuals with exocrine pancreatic cancer
    • First degree relatives of individuals diagnosed with exocrine pancreatic cancer
  • Genes that will likely be ordered include BRCA1/2, as well as ATM, CDKN2A, STK11, TP53 and most Lynch syndrome genes
  • Other benefits of testing include
    • Information and knowledge that could be of importance to other family members
    • New medications, specifically PARP (poly ADP-ribose polymerase) inhibitors, may be selected based on identification of mutations in the BRCA genes

Breast Cancer and AJ Population

  • 2.5% (1/40) individuals of Ashkenazi Jewish heritage (unselected – i.e. do not need high risk family history) will have one of the 3 founder BRCA1/2 variants vs 0.1% in the general population
    • Founder pathogenic variants: BRCA1 185delAG | BRCA1 5382insC | BRCA2 6174delT
    • 90% of pathogenic BRCA1/2 pathogenic variants belong to one of the 3 founder mutations
  • Previously, NCCN recommended offering genetic testing to AJ individuals if there was personal or family history
  • New guidance states testing may be considered in unaffected AJ individuals
    • The recommendation refers to the 3 founder mutations only
    • Ideally, testing should be offered in the context of longitudinal studies | If studies are not available, testing can be considered providing that pre-test education and access to post-test management is available

Additional Notes

  • Testing for high-penetrance breast and/or ovarian cancer susceptibility genes can also be considered
    • For women with bilateral breast cancer, first diagnosed between 50 and 65 years of age
    • Unaffected women who don’t meet the NCCN guidelines for personal or family history but have a probability of 2.5 to 5% of carrying a BRCA1/2 pathogenic variant (using validated calculators such as Tyrer-Cuzick | Prior to testing for variants in other high penetrance genes aside from BRCA1/2, NCCN recommends counseling and assessing patient preference, risk for VUS and cost/insurance

Note: High penetrance genes will usually include BRCA1/2, CDH1, PALB2, PTEN and TP53 with other genes included on some genetic testing panels as well

  • There is a low probability (<2.5%) of clinically useful findings on genetic testing if a patient has breast cancer
    • After age 65 and
    • No close relatives (first, second or third degree relatives on the same side of the family) with breast, ovarian, pancreatic or prostate cancer
  • NCCN continues to caution about the use of direct-to-consumer (DTC) genetic tests
    • DTC tests are not necessarily validated for clinical use
    • Comprehensive risk assessment is not provided because DTC tests usually do not include gross deletion or duplication analyses
    • Research on DTC tests have revealed false positive results as well as variant classification errors
    • Confirmatory germline testing by a certified clinical laboratory is recommended
    • Medical management based only on a DTC test is not recommended

Want to be notified when new guidelines are released? Get ObGFirst!

Learn More »


Learn More – Primary Sources:

NCCN GUIDELINES FOR DETECTION, PREVENTION, & RISK REDUCTION: Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic (free but requires sign-up)

Take a post-test and get CME credits

TAKE THE POST TEST

image_pdfFavoriteLoadingFavorite
< Previous
All Alerts Posts
Next >

Related ObG Topics:

USPSTF Guidelines for Primary Care Clinicians: BRCA-Related Cancer Risk Assessment
Should We Be Testing Beyond BRCA1/2 in Women of Ashkenazi Jewish Heritage with Breast Cancer?
USPSTF Guidance: When to Use Medication to Reduce Breast Cancer Risk
BRCA1 & BRCA2 Mutations: What Are the Risks for Developing Breast and Ovarian Cancer?
Cascade Testing: Notifying and Counseling Relatives of Individuals who are BRCA Mutation Carriers

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site